Jubilant Pharmova’s US Facility Concludes USFDA Inspection with No Sterility Concerns

Jubilant Pharmova Limited has announced the completion of a USFDA inspection at its subsidiary, Jubilant HollisterStier LLC (JHS), located in Spokane, Washington, on June 17, 2026. Key Highlights: Inspection Outcome: The USFDA issued eight observations following the audit. No Sterility Issues: Crucially, none of the observations relate to sterility assurance, affirming the facility's adherence to critical quality standards for its core operations. Next Steps: JHS will submit its formal response to address the findings within 15 business days. Strategic Context: JHS is a leading contract manufacturer specializing in sterile injectables and ophthalmic solutions. The absence of sterility-related observations is a highly positive outcome; it mitigates severe regulatory risks, ensures uninterrupted commercial manufacturing, and reinforces confidence in the facility's quality systems. $JUBLPHARMA